Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221513 · ClinicalTrials.gov registry record · Phase 2
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
A Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Group 2 Pulmonary Hypertension, sponsored by Salubris Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07221513: Recruiting Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Group 2 Pulmonary Hypertension, sponsored by Salubris Biotherapeutics.
NCT07221513 is a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Group 2 Pulmonary Hypertension that is actively recruiting participants, run by Salubris Biotherapeutics. The registered enrollment target is 30 participants, below the 9,876-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221513, a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Group 2 Pulmonary Hypertension, is actively recruiting participants, sponsored by Salubris Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.
Conditions Studied
Interventions
- DRUG JK07
Study Locations (1)
Oklahoma
- Saint Francis Heart and Vascular Institute - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT07221513 shows while recruiting
NCT07221513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 9,876-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with HFpEF - Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which JK07 is the first listed.
NCT07221513 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT07221513 about?
NCT07221513 is a clinical study titled "Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension". This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.
What is the current status of trial NCT07221513?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-12-15. Estimated completion is 2027-10.
What conditions does trial NCT07221513 study?
This clinical trial studies the following conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension, HFrEF - Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT07221513?
The interventions under investigation include: JK07 (DRUG).
Who is sponsoring clinical trial NCT07221513?
This trial is sponsored by Salubris Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221513 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HFpEF - Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tailored Exercise Training Study Among Adults With HFpEF
RECRUITING · Phase 2
-
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
RECRUITING · Phase 2
-
MOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
US Benchmarking Clinical Study
RECRUITING
-
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI